Sign in

CIK 0001231457

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

GENELUX Corp

Sign in to watch
Ticker
GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 805-267-9889
Business address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
  1. 4 Derivatives Options or other derivatives
  2. 4 Grant or award Director acquired 22,283 shares (grant or award)
  3. 4 Grant or award President and CEO acquired 361,200 shares (grant or award)
  4. 4 Grant or award Head of Regulatory acquired 26,230 shares (grant or award)
  5. 4 Grant or award Director acquired 22,283 shares (grant or award)
  6. 4 Grant or award SVP, Clinical Development acquired 101,480 shares (grant or award)
  7. 4 Grant or award Director acquired 22,283 shares (grant or award)
  8. 4 Grant or award Director acquired 22,283 shares (grant or award)
  9. 4 Grant or award Chief Technical Officer acquired 107,500 shares (grant or award)
  10. 4 Derivatives Options or other derivatives
  11. 3 Insider Initial Statement of Ownership
  12. 4 Gift Director gave 25,000 shares (gift)
  13. 4 Open-market sale General Counsel sold 4,475 shares at $2.92 ($13,067)
  14. 4 Open-market sale President and CEO sold 10,764 shares at $2.92 ($31,431)
  15. 4 Open-market sale VP, Clinical Trial Operations sold 5,579 shares at $2.92 ($16,291)
  16. 4 Open-market sale VP, Pharmaceutical Development sold 4,737 shares at $2.92 ($13,832)
  17. 4 Open-market sale Head of Regulatory sold 1,259 shares at $2.92 ($3,676)
  18. 4 Grant or award Head of Regulatory acquired 4,172 shares (grant or award)
  19. 4 Grant or award VP, Pharmaceutical Development acquired 13,350 shares (grant or award)
  20. 4 Grant or award VP, Clinical Trial Operations acquired 13,350 shares (grant or award)

Page 3 of 10 · 190 filings